# A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis

> **NCT02545868** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 102 (actual)

## Conditions studied

- Multiple Sclerosis, Relapsing-Remitting

## Interventions

- **BIOLOGICAL:** 23-PPV
- **BIOLOGICAL:** 13-PCV Booster
- **BIOLOGICAL:** Influenza Vaccine
- **BIOLOGICAL:** KLH
- **DRUG:** OCR
- **BIOLOGICAL:** TT Vaccine

## Key facts

- **NCT ID:** NCT02545868
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-27
- **Primary completion:** 2017-02-14
- **Final completion:** 2021-09-21
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2024-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02545868

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02545868, "A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02545868. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*